Tadalafil Tablet
Product Images NDC 68788-8292

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68788-8292). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Timelinedescription Automatically Generated With Medium Confidence (2354c3e2 7b5f 4fdd Bbf2 7fa3c57686f8 00)

Label for Tadalafil Tab 5 mg tablets, generic for Cialis, manufactured by Ajanta Pharma USA Inc. The label includes storage instructions, federal law caution regarding drug transfer, and directions for use in both English and Spanish. The product is film-coated and yellow, with the imprint T 5, distributed by Preferred Pharmaceuticals Inc.*

FDA Label Image

Figure8 (Tadalafil Fig8)

A line graph comparing the change from baseline in IPSS Total Score over 12 weeks of treatment between Tadalafil 5 mg and placebo. The y-axis shows score changes and the x-axis indicates duration of treatment in weeks. The graph shows greater score improvement with Tadalafil 5 mg compared to placebo, with significance noted at 12 weeks (p<0.01).*

FDA Label Image

Figure1 (Tadalafil Figure1)

A set of four line graphs showing changes in blood pressure over time. The graphs display the difference in standing systolic and diastolic blood pressure, as well as supine systolic and diastolic blood pressure, between tadalafil and placebo groups, measured in mmHg, across a 96-hour period.*

FDA Label Image

Figure2 (Tadalafil Figure2)

Two line graphs displaying standing and supine systolic blood pressure changes over 24 hours post-dose. The first graph shows standing systolic blood pressure (mmHg) over time comparing Tadalafil 20 mg with doxazosin 8 mg to placebo with doxazosin 8 mg. The second graph shows supine systolic blood pressure under the same conditions and timeframe.*

FDA Label Image

Figure3 (Tadalafil Figure3)

A line graph showing the effect on systolic blood pressure (in mmHg) over 12 hours after administration of tadalafil or placebo combined with doxazosin. Four groups are plotted: 20 mg tadalafil at 08:00 with 8 mg doxazosin at 08:00, placebo at 08:00 with 8 mg doxazosin at 08:00, 20 mg tadalafil at 20:00 with 8 mg doxazosin at 08:00, and placebo at 20:00 with 8 mg doxazosin at 08:00. The y-axis represents changes in systolic blood pressure, ranging approximately from -20 to +20 mmHg, and the x-axis indicates time in hours after administration.*

FDA Label Image

Figure4 (Tadalafil Figure4)

A pharmacokinetic curve depicting plasma tadalafil concentration (μg/L) over time (hours) following single 20-mg and 5-mg tadalafil doses, and once-daily 5-mg tadalafil after 5 consecutive days. The graph illustrates changes in drug concentration with error bars over a 120-hour period.*

FDA Label Image

Figure5 (Tadalafil Figure5)

A line graph showing the change from baseline in IPSS total score over 12 weeks of treatment comparing Tadalafil 5 mg and placebo. The x-axis represents duration of treatment in weeks, and the y-axis shows the change in IPSS score. The Tadalafil 5 mg line decreases more steeply than placebo, indicating greater score reduction, with a significant difference (p<0.01).*

FDA Label Image

Figure6 (Tadalafil Figure6)

A line graph comparing changes from baseline in IPSS total score for Tadalafil 5 mg tablets versus placebo over a 12-week treatment period. The x-axis shows duration in weeks, and the y-axis shows the change from baseline score. The graph indicates statistically significant improvement with Tadalafil compared to placebo at multiple time points.*

FDA Label Image

Figure7 (Tadalafil Figure7)

A line graph titled 'Weeks of Therapy' showing least squares mean change from baseline over 26 weeks. It compares treatment groups Tadalafil/Finasteride and Placebo/Finasteride, with data points at 0, 4, 12, and 26 weeks. Statistical annotations indicate significance levels (p<0.001 and p<0.05).*

FDA Label Image

Structure (Tadalafil Structure)

Chemical structure diagram of tadalafil, a human prescription oral tablet active ingredient. The diagram shows the molecular arrangement with labeled bonds and rings characteristic of tadalafil's chemical composition.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.